Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength

About 15% of Duchenne muscular dystrophy (DMD) cases are caused by point mutations leading to premature stop codons and disrupted synthesis of the dystrophin protein. Stop codon read-through therapy is available with the drug Ataluren (Translarna® by PTC Therapeutics). Following positive results in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi-Fakhari, Daniel, Dillmann, Ulrich, Flotats-Bastardas, Marina, Poryo, Martin, Abdul-Khaliq, Hashim, Shamdeen, Mohammed Ghiath, Mischo, Bernhard, Zemlin, Michael, Meyer, Sascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206203/
https://www.ncbi.nlm.nih.gov/pubmed/30406066
http://dx.doi.org/10.3389/fped.2018.00316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206203/
https://www.ncbi.nlm.nih.gov/pubmed/30406066
http://dx.doi.org/10.3389/fped.2018.00316

Ejemplares similares